Does Arkansas Blue Cross Cover Zepbound? Exceptions and Appeals

Arkansas Blue Cross and Blue Shield does not cover Zepbound when it is prescribed for weight loss. The insurer treats weight-loss medications as a non-covered benefit across its commercial plans and through its Health Advantage HMO affiliate, and a December 2023 provider bulletin named Zepbound specifically among the drugs excluded from the formulary.¹ There are narrow paths worth knowing about, and manufacturer pricing that softens the out-of-pocket blow.

Why the Exclusion Exists

Zepbound and Mounjaro share an active ingredient, tirzepatide, but their FDA approvals differ. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in adults with obesity and, since December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity.² That labeling is what drives coverage.

The December 2023 bulletin stated that “weight loss drugs are not a covered benefit for Arkansas Blue Cross and Blue Shield or Health Advantage members,” listing Saxenda, Wegovy, and Zepbound as drugs kept off the formulary because their FDA-approved indications are for weight loss. Mounjaro and Ozempic remain covered when prescribed for type 2 diabetes, but every GLP-1 prescription now requires confirmation of a diabetes diagnosis, either through a diagnosis code on the prescription or through prior authorization with medical records.¹

The exclusion is legal because the Affordable Care Act does not require insurers to cover drugs for “anorexia, weight loss, or weight gain” as part of Essential Health Benefits.³ Wendy See, vice president of primary care and pharmacy programs at Arkansas Blue Cross, said individual members have asked for coverage but employer groups have not pushed for it: “We have members asking why we’re not covering them, but we’re not seeing groups say we should cover them.”⁴

How the Exclusion Applies to Your Plan

The answer is the same across most Arkansas Blue Cross products, but the mechanics differ slightly.

On commercial plans (PPO, HMO, POS, employer-sponsored), Zepbound carries a prior authorization requirement, but the underlying benefit exclusion for weight-loss drugs means prior authorization does not translate into approval for weight-loss use.⁵ Health Advantage HMO plans apply the same exclusion, while continuing to cover GLP-1 drugs for type 2 diabetes.⁴ Marketplace exchange PPO and POS plans list prior authorization as well, and the same weight-loss exclusion governs the benefit.

ARBenefits, the plan for Arkansas state and public school employees administered by Health Advantage, has historically not covered weight-loss medications.⁶ A November 2024 legislative subcommittee recommended a diabetes management program for the Employee Benefits Division with “control over GLP-1 drug costs,” but the focus was diabetes, not weight loss.⁷

Arkansas Medicaid restricts GLP-1 coverage to type 2 diabetes and does not cover the drugs for obesity.⁸ Arkansas Total Care, a Medicaid managed care organization, likewise classifies GLP-1 weight-loss use as non-covered.⁹

The Sleep Apnea Route

The 2024 FDA approval of Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity opened a separate clinical indication that some national insurers now treat apart from weight loss. UnitedHealthcare, for example, covers Zepbound for OSA under its clinical pharmacy program even where weight-loss use is excluded, subject to sleep study findings, BMI, and CPAP-related criteria.¹⁰

Arkansas Blue Cross has not published a standalone OSA policy for Zepbound. If you carry a qualifying sleep apnea diagnosis, your prescriber can submit a prior authorization or formulary exception request framed around OSA rather than weight management. That is a possibility to test with your plan, not a guaranteed pathway.

Requesting an Exception and Appealing a Denial

The exception process starts with your prescriber. A Letter of Medical Necessity on the provider’s letterhead should include your name and member ID, the diagnosis, therapies you have tried and failed, and supporting records. It is faxed to the Arkansas Blue Cross pharmacy department at 501-378-6980.¹¹

If the exception is denied, you have 180 days from the denial notice to file a written internal appeal. Send it to Appeals Coordinator, Arkansas Blue Cross and Blue Shield, PO Box 2181, Little Rock, AR 72203-2181, with the envelope marked “Internal Review Request.” Urgent appeals can be faxed to 501-379-1214.¹²

If the internal appeal fails, you can request an external review through the Arkansas Insurance Department within four months of the denial. The independent reviewer’s decision binds both sides. Standard reviews take up to 45 days; expedited reviews, used when delay could jeopardize your life or health, are decided within 72 hours.¹¹

Because the exclusion is a benefit design decision rather than a medical necessity call, appeals for weight-loss use face long odds. Members with complex clinical pictures beyond weight management, and those with a documented OSA indication, have the strongest arguments.

What Zepbound Costs Without Coverage

Manufacturer list prices run from $499 to about $1,086 for a 28-day supply depending on dose, and average retail pricing for the single-dose pen reaches roughly $1,291 per month.¹³ Eli Lilly runs several programs that lower those numbers:

The Zepbound Savings Card lets patients with commercial insurance that excludes Zepbound pay as little as $499 per month for the single-dose pen. This is the path most Arkansas Blue Cross members will use.¹⁴
Patients whose commercial insurance covers Zepbound can pay as little as $25 per month through the same card, with annual savings capped at $1,300. This scenario rarely applies with Arkansas Blue Cross.¹⁴
Self-pay KwikPen pricing through LillyDirect is $299 per month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for doses from 7.5 mg through 15 mg, provided refills are purchased within 45 days of the previous fill.¹⁵

Patients enrolled in Medicare, Medicaid, TRICARE, VA, or other government insurance are excluded from all Lilly savings programs. The current programs expire December 31, 2026.¹⁴

Where Arkansas Law Stands

No Arkansas statute requires private insurers or Medicaid to cover GLP-1 drugs for weight loss.¹⁶ Rep. Aaron Pilkington introduced HB 1332 in 2025, which would have directed Arkansas Medicaid to evaluate obesity-related claims data and associated costs. The bill passed the House on April 10, 2025, but died in the Senate Public Health, Welfare and Labor Committee when the legislature adjourned on May 5, 2025.¹⁷

Arkansas Blue Cross has said it is exploring options for employer groups that want to add weight-loss drug coverage, including group riders that would require prior authorization or step therapy, while noting any addition would raise premiums for the entire group.⁴ Until an employer group opts in or state law changes, the default remains exclusion.

1
Arkansas Blue Cross and Blue Shield. Provider News, December 2023
2
FDA. FDA Approves First Medication for Obstructive Sleep Apnea
3
HealthInsurance.org. Does Health Insurance Cover Drugs Used for Weight Loss
4
Health Benefit Insight. The Inside Scoop on GLP-1 Weight Loss Drugs
5
PrescriberPoint. Zepbound Coverage – Arkansas Blue Cross and Blue Shield
6
GW School of Public Health. State Employee Obesity Coverage – Arkansas
7
Arkansas Department of Finance and Administration. Arkansas Panel Endorses Diabetes Management Program
8
KFF. Medicaid Coverage of and Spending on GLP-1s
9
Arkansas Total Care. GLP-1 Agonists for Weight Loss
10
UnitedHealthcare. Prior Auth – Zepbound
11
Arkansas Blue Cross and Blue Shield. Drug Exceptions Time Frames
12
Arkansas Blue Cross and Blue Shield. How To File an Appeal
13
Eli Lilly and Company. Zepbound Pricing Information
14
Eli Lilly and Company. Zepbound Savings
15
Eli Lilly and Company. Zepbound Coverage and Savings
16
MultiState. GLP-1 Weight Loss Drugs Coverage Under Medicaid and Other Health Plans
17
Arkansas Legislature. HB 1332 Bill Detail